Celltrion
R&D/ Views & Analysis/ Views and analysis
COVID-19: Celltrion’s therapeutic option
Catherine Longworth
Celltrion, COVID-19, CT-P59, ema
0 Comment
CHMP backs Celltrion’s regdanvimab antibody for COVID-19
Phil Taylor
Celltrion, CHMP, coronavirus, COVID-19, Diurnal, ema, EU, Janssen, Johnson & Johnson, Verastem
0 Comment
Celltrion closes in on COVID-19 antibody market after trial success
Richard Staines
Celltrion, COVID-19, Eli Lilly, R&D
0 Comment
Celltrion buys drug portfolio from Takeda, ventures into chronic diseases
Richard Staines
Celltrion, chronic diseases, Diabetes, hypertension, M&A, Takeda
0 Comment
Celltrion trials infliximab biosimilar in recovering COVID-19 patients
Richard Staines
Celltrion, coronavirus, COVID-19, R&D
0 Comment
Celltrion to develop coronavirus antibody and fast test
Richard Staines
antiviral, Celltrion, coronavirus, diagnostics, infectious diseases, R&D
0 Comment
Celltrion plans to launch a biosimilar each year for next decade
Richard Staines
biosimilar, Celltrion, market access
0 Comment
Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Celltrion gears up for subcutaneous infliximab launch in Europe
Richard Staines
biosimilars, Celltrion, IBD, infliximab, Rheumatoid arthritis
0 Comment